IL6 and COVID-19: Recent studies demonstrated that some immunosuppressants, such as anti-IL-6 and other biological disease-modifying anti-rheumatic drugs (bDMARDs), may provide a certain level of protection against COVID-19, but the actual impact of anti-rejection immunosuppressive treatment on the COVID-19 disease severity is unclear [58,59,60].